KR930000517A - 이미다조디아제핀 - Google Patents
이미다조디아제핀 Download PDFInfo
- Publication number
- KR930000517A KR930000517A KR1019920010394A KR920010394A KR930000517A KR 930000517 A KR930000517 A KR 930000517A KR 1019920010394 A KR1019920010394 A KR 1019920010394A KR 920010394 A KR920010394 A KR 920010394A KR 930000517 A KR930000517 A KR 930000517A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- group
- lower alkyl
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- BMGXAZCDDYTVFV-UHFFFAOYSA-N imidazo[4,5-c]diazepine Chemical compound C1=CN=NC2=NC=NC2=C1 BMGXAZCDDYTVFV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- -1 heteroaroyloxy Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003435 aroyl group Chemical group 0.000 claims 2
- 150000007514 bases Chemical class 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- BSGOHMQXEGBBHL-UHFFFAOYSA-N 3h-[1,2,4]triazolo[1,5-d][1,4]benzodiazepine Chemical compound C1=CN2NC=NC2=C2C=CC=CC2=N1 BSGOHMQXEGBBHL-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000012876 carrier material Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 150000002527 isonitriles Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1791/91 | 1991-06-17 | ||
| CH179191 | 1991-06-17 | ||
| CH114092 | 1992-04-08 | ||
| CH1140/92 | 1992-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930000517A true KR930000517A (ko) | 1993-01-15 |
Family
ID=25686778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920010394A Withdrawn KR930000517A (ko) | 1991-06-17 | 1992-06-16 | 이미다조디아제핀 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5387585A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0519307A3 (cg-RX-API-DMAC10.html) |
| JP (1) | JPH078869B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR930000517A (cg-RX-API-DMAC10.html) |
| AU (1) | AU655472B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2069382A1 (cg-RX-API-DMAC10.html) |
| CZ (1) | CZ185092A3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI922827A7 (cg-RX-API-DMAC10.html) |
| HU (1) | HU9201929D0 (cg-RX-API-DMAC10.html) |
| IE (1) | IE921945A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL102175A0 (cg-RX-API-DMAC10.html) |
| IS (1) | IS3878A (cg-RX-API-DMAC10.html) |
| NO (1) | NO922367L (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ243091A (cg-RX-API-DMAC10.html) |
| TW (1) | TW201311B (cg-RX-API-DMAC10.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW349100B (en) * | 1994-11-11 | 1999-01-01 | Hoffmann La Roche | Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines |
| JPH10298078A (ja) * | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | 抗不安薬 |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| US6686352B2 (en) * | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| EP1461323B1 (en) * | 2001-06-12 | 2013-10-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| MX2007004250A (es) * | 2004-10-12 | 2007-06-12 | Hoffmann La Roche | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. |
| MX2007004640A (es) * | 2004-10-20 | 2007-06-08 | Hoffmann La Roche | Derivados de benzodiazepina sustituidos con halogeno. |
| BRPI0519991A2 (pt) | 2004-10-20 | 2009-04-07 | Hoffmann La Roche | derivados de imidazo-benzodiazepina |
| BRPI0515800A (pt) | 2004-12-14 | 2008-08-05 | Hoffmann La Roche | imidazo-benzodiazepinas tetracìclicas como moduladores de receptores de gaba |
| WO2007042421A1 (en) | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Imidazo benzodiazepine derivatives |
| US9322831B2 (en) | 2008-09-23 | 2016-04-26 | The Johns Hopkins University | DDX3 as a biomarker for cancer and methods related thereto |
| JP5802872B2 (ja) * | 2008-09-23 | 2015-11-04 | ザ ジョンズ ホプキンズ ユニヴァーシティー | 縮合ジイミダゾジアゼピン化合物並びにその使用及び製造方法 |
| AU2014240289B2 (en) * | 2008-09-23 | 2015-12-03 | The Johns Hopkins University | Fused diimidazodiazepine compounds and methods of use and manufacture thereof |
| WO2012068161A1 (en) | 2010-11-15 | 2012-05-24 | Agenebio, Inc. | Pyridazine derivatives, compositions and methods for treating cognitive impairment |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| MX381561B (es) | 2013-12-20 | 2025-03-12 | Agenebio Inc | Derivados de benzodiazepina, composiciones, y métodos para tratar el deterioro cognitivo. |
| KR102708045B1 (ko) | 2015-03-10 | 2024-09-23 | 오리진 온콜로지 리미티드 | 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물 |
| CU20170118A7 (es) * | 2015-03-10 | 2018-02-08 | Aurigene Discovery Tech Ltd | Compuestos de tiadiazol y 1,2,4-oxadiazol 3-sustituidos como inmunomoduladores |
| CN113264939A (zh) * | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
| WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio, Inc. | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| KR102736865B1 (ko) | 2017-06-21 | 2024-12-03 | 샤이 테라퓨틱스 엘엘씨 | 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| CN111194308A (zh) | 2017-10-11 | 2020-05-22 | 奥瑞基尼探索技术有限公司 | 3-取代的1,2,4-噁二唑的结晶形式 |
| WO2019087087A1 (en) | 2017-11-03 | 2019-05-09 | Aurigene Discovery Technologies Limited | Dual inhibitors of tim-3 and pd-1 pathways |
| EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
| EA202190076A1 (ru) | 2018-06-19 | 2021-09-22 | Эйджинбайо, Инк. | Производные бензодиазепина, композиции и способы лечения когнитивных нарушений |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1143728A (en) * | 1979-10-04 | 1983-03-29 | Max Gerecke | Imidazodiazepine derivatives |
| ZW985A1 (en) * | 1984-01-19 | 1985-08-28 | Hoffmann La Roche | Imidazodiazepine derivatives |
| US4897392A (en) * | 1989-07-03 | 1990-01-30 | Hoechst-Roussel Pharmaceuticals, Inc. | 4H-indolo(1,2-d)(1,2,4)triazolo(4,3-A)(1,4)benzodiazepines |
| DK443589D0 (da) * | 1989-09-08 | 1989-09-08 | Ferrosan As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| DK41191D0 (da) * | 1991-03-07 | 1991-03-07 | Novo Nordisk As | Heterocycliske forbindelser, deres fremstilling og anvendelse |
-
1992
- 1992-05-15 TW TW081103807A patent/TW201311B/zh active
- 1992-05-25 CA CA002069382A patent/CA2069382A1/en not_active Abandoned
- 1992-06-10 HU HU9201929A patent/HU9201929D0/hu unknown
- 1992-06-10 NZ NZ243091A patent/NZ243091A/en unknown
- 1992-06-10 EP EP19920109745 patent/EP0519307A3/de not_active Withdrawn
- 1992-06-11 IL IL102175A patent/IL102175A0/xx unknown
- 1992-06-12 JP JP4179406A patent/JPH078869B2/ja not_active Expired - Lifetime
- 1992-06-12 AU AU18234/92A patent/AU655472B2/en not_active Ceased
- 1992-06-12 IS IS3878A patent/IS3878A/is unknown
- 1992-06-16 KR KR1019920010394A patent/KR930000517A/ko not_active Withdrawn
- 1992-06-16 CZ CS921850A patent/CZ185092A3/cs unknown
- 1992-06-16 NO NO92922367A patent/NO922367L/no unknown
- 1992-06-17 FI FI922827A patent/FI922827A7/fi not_active Application Discontinuation
- 1992-07-01 IE IE194592A patent/IE921945A1/en not_active Application Discontinuation
-
1993
- 1993-11-15 US US08/153,234 patent/US5387585A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL102175A0 (en) | 1993-01-14 |
| AU655472B2 (en) | 1994-12-22 |
| HU9201929D0 (en) | 1992-08-28 |
| NO922367D0 (no) | 1992-06-16 |
| CA2069382A1 (en) | 1992-12-18 |
| NZ243091A (en) | 1994-11-25 |
| AU1823492A (en) | 1992-12-24 |
| FI922827A0 (fi) | 1992-06-17 |
| JPH078869B2 (ja) | 1995-02-01 |
| EP0519307A3 (en) | 1993-04-21 |
| CZ185092A3 (en) | 1993-12-15 |
| IE921945A1 (en) | 1992-12-30 |
| US5387585A (en) | 1995-02-07 |
| IS3878A (is) | 1992-12-18 |
| TW201311B (cg-RX-API-DMAC10.html) | 1993-03-01 |
| EP0519307A2 (de) | 1992-12-23 |
| JPH05202051A (ja) | 1993-08-10 |
| NO922367L (no) | 1992-12-18 |
| FI922827A7 (fi) | 1992-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930000517A (ko) | 이미다조디아제핀 | |
| KR100843281B1 (ko) | 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약 | |
| JP2020536881A5 (cg-RX-API-DMAC10.html) | ||
| GB2262093B (en) | Piperazine derivatives | |
| IL104305A0 (en) | Piperazine derivatives,their preparation and pharmaceutical compositions containing them | |
| JP2004520285A (ja) | 新規なラクタム置換ピラゾロピリジン誘導体 | |
| JPH08508979A (ja) | 複素環式化合物およびそれらの製法および使用 | |
| CA2091874A1 (en) | Triazolopyridazine compounds, their production and use | |
| JPS62249985A (ja) | ベンゾジアゼピン誘導体、その製法、並びにそれを使用する中枢神経病治療剤 | |
| PT84881A (en) | Process for the preparation of 4(5)-substituted imidazole derivatives | |
| KR890003764A (ko) | 헤테로사이클 화합물 | |
| SG178717A1 (en) | 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors | |
| KR20240024906A (ko) | 설폭시민 화합물 및 이의 용도 | |
| FR2717813A1 (fr) | Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant . | |
| EP0623620B1 (fr) | Dérivés de pyrrolopyrazines à activité 5-HT3 | |
| EP0743945A1 (en) | Heterocyclic compounds and their preparation and use | |
| CA2102318A1 (fr) | Derives de 1,2,4-thiadiazino[3,4-b]benzothiazole, leur preparation et les medicaments les contenant | |
| KR0183395B1 (ko) | 2,4,8-삼치환된 3H,6H-1,4,5a,8a-테트라아자아세나프틸렌-3,5-(4H)-디온화합물, 및 이의 제조방법 | |
| KR930701442A (ko) | 헤테로시클릭 화합물과 그의 제조방법 및 용도 | |
| US3905980A (en) | 3-Substituted-2,4-dihydro-benzodiazepines | |
| KR940007008A (ko) | 1, 3, 4-벤조트리아제핀-5(4h)-온 유도체 및 이것의 제조 방법 | |
| GB9021571D0 (en) | Heterocyclic acids | |
| JPH0649067A (ja) | ４，５−ジヒドロピラゾロ〔３，４−ａ〕アクリジン類、それらの製造方法および医薬としてのそれらの使用 | |
| Conor et al. | Formation of polysubstituted pyridin-2-one derivatives by Michael addition of 3-oxobutanamide to α, β-ethylenic ketones and amides | |
| JPH045675B2 (cg-RX-API-DMAC10.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19920616 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |